每日200毫克加替沙星治疗老年患者细菌性社区获得性肺炎的临床疗效
Clinical effect of gatifloxacin, 200 mg daily, on bacterial community-acquired pneumonia in the elderly.
作者信息
Okimoto Niro, Kibayashi Takashi, Mimura Kimihiro, Yamato Kenji, Kurihara Takeyuki, Honda Yoshihiro, Osaki Kohichi, Asaoka Naoko, Ohba Hideo
机构信息
Center of Respiratory Diseases, Kawasaki Medical School Kawasaki Hospital, 2-1-80 Nakasange, Okayama 700-8505, Japan.
出版信息
J Infect Chemother. 2005 Dec;11(6):274-7. doi: 10.1007/s10156-005-0410-2.
The clinical effect of gatifloxacin (GFLX) at 200 mg daily (half of common dosage) on bacterial community-acquired pneumonia in the elderly was examined. Subjects were 30 patients with bacterial community-acquired pneumonia aged 65 years or more (mild, 21 patients; moderate, 9 patients), and GFLX at 100 mg per dose was administered twice daily for 4-14 days. The results included clinical effectiveness in 21 of 21 mildly affected patients (efficacy rate, 100%), in 8 of 9 moderately affected patients (efficacy rate, 88.9%), and 29 of a total of 30 patients (efficacy rate, 96.7%). With regard to bacteriological effect, 28 of 29 strains were eradicated (eradication rate, 96.6%). Abnormal laboratory findings included mild elevations in GPT, GOT, and ALP in only 1 patient. Based on these findings, we concluded that administration of GFLX at 200 mg daily is recommended for bacterial community-acquired pneumonia in the elderly.
研究了加替沙星（GFLX）每日200mg（常规剂量的一半）对老年细菌性社区获得性肺炎的临床疗效。研究对象为30例65岁及以上的细菌性社区获得性肺炎患者（轻度21例，中度9例），给予GFLX每剂量100mg，每日两次，持续4 - 14天。结果显示，21例轻度患者中有21例临床有效（有效率100%），9例中度患者中有8例有效（有效率88.9%），30例患者中共有29例有效（有效率96.7%）。在细菌学疗效方面，29株菌株中有28株被清除（清除率96.6%）。实验室检查异常仅1例患者出现GPT、GOT和ALP轻度升高。基于这些结果，我们得出结论，对于老年细菌性社区获得性肺炎，推荐每日给予200mg加替沙星。
Zotero 插件